Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 10/20 | 0.65 |
| ▸ | PDE3A | Q14432 | 10/20 | 0.65 |
| ▸ | PDE2A | O00408 | 6/20 | 0.65 |
| ▸ | P2RY12 | Q9H244 | 8/20 | 0.64 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 3/20 | 0.49 |
| ▸ | ACSL1 | P33121 | 2/20 | 0.48 |
| ▸ | ACSL6 | Q9UKU0 | 2/20 | 0.48 |
| ▸ | ALB | P02768 | 1/20 | 0.47 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3400442 | 0.80 | DRD2 (0.49) | PDE3BPDE3APDE2AP2RY12DRD2 | |
| SCHEMBL15932952 | 0.80 | MAPT (0.60) | PDE3BPDE3AP2RY12DRD2 | |
| SCHEMBL10657144 | 0.79 | PDE3B (1.00) | PDE3BPDE3APDE2AP2RY12 | |
| SCHEMBL9036354 | 0.79 | PDE3B (0.58) | PDE3BPDE3APDE2AP2RY12DRD2 | |
| SCHEMBL252370 | 0.78 | DRD2 (0.50) | PDE3BPDE3APDE2AP2RY12DRD2 | |
| SCHEMBL9369166 | 0.77 | PDE3B (0.56) | PDE3BPDE3APDE2AP2RY12SERPINE1 | |
| SCHEMBL31448470 | 0.77 | PPARA (0.73) | SERPINE1PPARAALB | |
| SCHEMBL7406783 | 0.76 | MAPT (0.51) | PDE3BPDE3APDE2AP2RY12DRD2 | |
| SCHEMBL6767845 | 0.76 | MAPT (0.60) | PDE3BPDE3AP2RY12DRD2 | |
| SCHEMBL12321247 | 0.76 | MAPT (0.51) | PDE3BPDE3APDE2AP2RY12DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023722-A1 | AMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY | 2009-01-22 | — | — | US | disclosed |
| US-7393859-B2 | Amide substituted imidazoquinolines | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| EP-1187613-B9 | AMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2006-10-25 | — | — | EP | disclosed |
| EP-1187613-B1 | AMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2006-08-09 | — | — | EP | disclosed |
| US-20040229897-A1 | Amide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-11-18 | — | — | US | disclosed |
| US-6756382-B2 | SECONDARY AMIDES SUCH AS N-(4-(4-AMINO-2-(2-METHOXYETHYL)-1H-IMIDAZO(4,5-C)QUINOLIN-1-YL)BUTYL)-1 -METHYL-5-OXO-2-PYRIDIN-3-YLPYRROLIDINE-3-CARBOXAMIDE; BIOSYNTHESIS OF CYTOKINES; PROPYLAXIS OF VIRAL DISEASES; IMMUNOLOGY MODULATORS | 3M INNOVATIVE PROPERTIES COMPANY | 2004-06-29 | — | — | US | disclosed |
| US-20030144283-A1 | Amide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-07-31 | — | — | US | disclosed |
| US-6451810-B1 | AID IN CYTOKINE BIOSYNTHESIS | 3M INNOVATIVE PROPERTIES COMPANY | 2002-09-17 | — | — | US | disclosed |
| EP-1187613-A4 | AMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2002-07-24 | — | — | EP | disclosed |
| EP-1187613-A1 | AMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2002-03-20 | — | — | EP | disclosed |
| WO-2000076505-A1 | AMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229897-A1 | Amide substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | PDE3B 2858/4885PDE3A 3429/4885PDE2A 2693/4885 |
| US-20090023722-A1 | AMIDE SUBSTITUTED IMIDAZOQUINOLINES | IFNG, IRF3, EIF2AK2 | PDE3B 2858/4885PDE3A 3429/4885PDE2A 2693/4885 |
| US-20030144283-A1 | Amide substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | PDE3B 2858/4885PDE3A 3429/4885PDE2A 2693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.